1 completed, 1 terminated. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Completed 1 |
| Phase 2 | 1 | Terminated 1 |
Follow B-Cell Activating Factor: new trials by email Literature Review of B-Cell Activating Factor trials Research Report on B-Cell Activating Factor
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| B-Lymphocyte Stimulator (BLyS) To Treat Selective IgA Deficiency B-Lymphocyte Stimulator (BLyS) - IgA Deficiency | Phase 1 | Completed | National Cancer Institute (NCI) | 20 | 2001-10-01 | 2016-09-22 |
| Vaccine Therapy Followed by Biological Therapy in Treating Patients With Stage III or Stage IV Melanoma MART-1 antigen, aldesleukin, gp100 antigen - Melanoma (Skin) | Phase 2 | Terminated | University of Southern California | 25 | 1999-06-01 | 2014-05-22 |
IgA Deficiency (1) · Immunologic Deficiency Syndromes (1) · Melanoma (1) · Neoplasms (1)
National Cancer Institute (NCI) (1) · University of Southern California (1)
United States (2)